MaxCyte, Inc. Proceeds from Issuance or Sale of Equity
MaxCyte, Inc. (MXCT) reported Proceeds from Issuance or Sale of Equity of GBP 40.20 million for the 1-month period ending 2021-02-28, per its 10-K filed 2023-03-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2023-03-15
- 2021-02-28: Proceeds from Issuance or Sale of Equity 1 month 40.20M GBP.
GBP
| Period end | Proceeds from Issuance or Sale of Equity 1 month |
|---|---|
| 2021-02-28 | 40.20M GBP 10-K · filed 2023-03-15 |
USD
| Period end | Proceeds from Issuance or Sale of Equity 1 month |
|---|---|
| 2021-02-28 | $55.30M 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |